Identity
Klotho is a protein named after the Greek Fate who spins the thread of life. The form that matters for ageing research is α-Klotho, encoded by the KL gene — a single-pass transmembrane protein of roughly 130 kDa, expressed most strongly in the kidney, choroid plexus and parathyroid. Its extracellular domain can be cleaved and released into blood, cerebrospinal fluid and urine as soluble (secreted) Klotho, which is the circulating form measured in human studies and the form most longevity interest attaches to.
Two distinct biological roles matter. As a co-receptor for FGF23, membrane α-Klotho is central to phosphate and vitamin D metabolism — this is established endocrinology, not speculation. As a circulating hormone-like factor, soluble Klotho has been reported to modulate insulin/IGF-1 signalling, oxidative stress responses, Wnt signalling and fibrosis pathways, which is where the ageing story comes from. (Related but separate proteins β-Klotho and γ-Klotho serve as co-receptors for other FGFs and are not the subject of longevity claims.)
Development & history
- 1997: Kuro-o and colleagues, working in mice, accidentally disrupted an unknown gene and produced animals with a startling accelerated ageing phenotype — short lifespan, skin atrophy, osteoporosis, atherosclerosis, emphysema, vascular calcification. They named the gene klotho (Nature).
- 2005: Kurosu et al. showed the converse: overexpressing Klotho extended lifespan in mice (Science), establishing it as one of the few single genes with a bidirectional lifespan effect.
- 2000s–2010s: Mechanistic work established the FGF23 co-receptor role and mapped Klotho's involvement in phosphate handling, vascular calcification and chronic kidney disease. A validated ELISA for soluble α-Klotho (2010) opened the door to human observational studies.
- 2010s–2020s: A very large observational literature accumulated, associating higher circulating Klotho with better cardiovascular, renal, cognitive and mortality outcomes across cohorts. Klotho became a standard longevity biomarker.
- 2025: Roig-Soriano et al. (Mol Ther) reported effects of the secreted form (s-KL) in normally ageing and progeroid mice; AAV-vector approaches reported substantial murine lifespan extension. Klotho Neurosciences (NASDAQ: KLTO) publicised preclinical gene-therapy work.
- February 2026: The first human trial of a Klotho-raising agent begins. Klothea Bio starts recruiting for a randomised, double-blind, placebo-controlled phase 1b of AKL003, an alpha-Klotho mRNA therapeutic given as two intravenous administrations about four weeks apart, at the GARM Clinic in Próspera, Roatán, Honduras. Endpoints: safety, tolerability, and whether serum α-Klotho actually rises — with exploratory biomarkers including inflammatory and metabolic markers, cardiovascular assessments, wearable sleep and recovery data, mitochondrial function, epigenetic clocks and quality-of-life measures.
Mechanism (as proposed)
The ageing-relevant proposals rest on soluble Klotho acting as a systemic factor: suppressing insulin/IGF-1 signalling (the pathway most consistently linked to lifespan across species), increasing resistance to oxidative stress, inhibiting Wnt signalling (implicated in stem-cell exhaustion), and restraining fibrosis in kidney, heart and lung. Membrane Klotho's FGF23 co-receptor role ties it directly to phosphate and vitamin D homeostasis — which is both a real mechanism and the most obvious safety consideration for any intervention that raises Klotho systemically.
The delivery problem is central and explains the shape of the field. Klotho is large, membrane-anchored, and unstable as a purified protein; simply administering it has never been made to work well. That is why the first human attempt uses mRNA to have the body make it, and why gene-therapy approaches dominate the preclinical pipeline — and equally why anything sold as an oral "Klotho supplement" has no plausible route to delivering the actual protein.
Reading the evidence honestly
Klotho is a case where the underlying science is unusually good and the consumer-facing story is almost entirely unsupported. Three separations do the work.
Mouse causation is established; human causation is not. The bidirectional mouse result — knockout accelerates ageing, overexpression extends life — is genuinely impressive and has held up for nearly thirty years. But the ageing field's graveyard is full of mouse lifespan findings that did not translate, and no human intervention study has existed until now.
The human data are observational, and the causal arrow is ambiguous. Circulating Klotho declines with age and tracks with worse outcomes, which is consistent with Klotho loss driving decline — and equally consistent with Klotho falling because of kidney disease, inflammation and illness. Low Klotho as a marker of being unwell explains the same correlations. Observational data cannot settle this, and no amount of additional cohort work will.
"First human trial" is not "proven". The AKL003 study is a phase 1b in healthy volunteers, asking whether repeat dosing is tolerated and whether the biomarker moves. It is not powered for, and does not attempt, any health outcome — the sponsors say as much. Its location in a special jurisdiction chosen partly to enable non-standard development is relevant context, not a disqualification, but it means the results will need careful independent scrutiny.
Finally, the consumer layer deserves to be named plainly. Anything sold as a "Klotho supplement", "Klotho peptide" or "Klotho activator" is not the protein in these studies. Compounds marketed as Klotho boosters — berberine, resveratrol and similar — have preclinical pathway associations, which is a very long way from raising human Klotho or extending human healthspan. The prestige of an excellent body of ageing biology is being lent to products that have no part in it.